The Cosentyx drug market provides a monoclonal antibody for the treatment of moderate to severe plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis. Cosentyx selectively inhibits interleukin-17A, an important cytokine involved in inflammatory and immune responses. Being at the forefront of targeted biologic therapy, Cosentyx has revolutionized treatment approaches for many patients suffering from chronic inflammatory diseases.
The global Cosentyx drug market is estimated to be valued at US$ 5.72 billion in 2025 and is expected to exhibit a CAGR of 7.5% over the forecast period 2025-2032.
Key Takeaways
Key players operating in the Cosentyx drug market are Novartis, Pfizer, Roche. Key players related content comprises key players related content (Key players operating in the Cosentyx drug market are Novartis, Pfizer, Roche.).
Cosentyx Drug Market Demand can be attributed to rising prevalence of various autoimmune diseases and increasing awareness regarding available treatment options. However, patent expiration of blockbuster drugs and introduction of biosimilars may restrain the growth of the market to some extent. Furthermore, the market is witnessing expansion in emerging economies of Asia Pacific and Latin America owing to improving healthcare infrastructure and rising healthcare expenditure in these regions.
Market key trends
The biosimilars trend is a key trend being witnessed in the Cosentyx drug market currently. As the patent of Cosentyx expires in 2024, many pharmaceutical companies are investing heavily in development of biosimilar versions which are expected hit the market soon. This will increase treatment affordability and accessibility. However, biosimilars may pose a pricing challenge for the innovator drug. Overall, increasing adoption of biosimilars is likely to shape the future landscape of the Cosentyx drug market between 2024-2031.
Porter’s Analysis
Threat of new entrants: High capital requirements and established brand loyalty pose barriers for new competitors.
Bargaining power of buyers: Individual customers have low bargaining power due to availability of few treatment alternatives. Insurance companies have some influence over pricing. Bargaining power of suppliers: Novartis has control over production and supply of Cosentyx. Rare diseases focus limits viable treatment alternatives strengthening supplier power.
Threat of new substitutes: Pipeline drugs from competitors pose a potential threat, however maintaining first-to-market advantages and patents provide protection against substitutes in the forecast period.
Competitive rivalry: Competition is intensifying with approval of new mechanisms of action for treating plaque psoriasis and psoriatic arthritis.
Rivals are striving for addition of new indications to gain market share. The US accounts for over 40% of the global Cosentyx drug market value owing to high treatment costs and strong private and public drug reimbursement. Being the largest pharmaceutical market, initiatives by payers to expand access to biologics are benefiting the drug market. The Asia Pacific region is emerging as the fastest growing geographical market for Cosentyx led by increasing healthcare expenditures, economic growth and rising standards of care in countries like China and India. Growing dermatology patient pools along with initiatives by the drug maker to penetrate emerging markets through patient assistance programs are favoring high growth rates compared to mature markets like the US and Europe.
Get This Report in Japanese Language: コセンティクス医薬品市場
Get This Report in Korean Language: 코센텍스 의약품 시장
About Author:
Vaagisha brings over three years of expertise as a content editor in the market research domain. Originally a creative writer, she discovered her passion for editing, combining her flair for writing with a meticulous eye for detail. Her ability to craft and refine compelling content makes her an invaluable asset in delivering polished and engaging write-ups.
(LinkedIn: https://www.linkedin.com/in/vaagisha-singh-8080b91)
